Page last updated: 2024-09-03

vadimezan and Triple Negative Breast Neoplasms

vadimezan has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barrera, V; DeCristo, MJ; Freedman, RA; Goreczny, GJ; Hutchinson, JN; Laszewski, T; McAllister, SS; Mittendorf, EA; Morrow, S; Qin, Y; Sceneay, J; Stover, DG; Ubellacker, JM; Wilson, K	1

Other Studies

1 other study(ies) available for vadimezan and Triple Negative Breast Neoplasms

Article	Year
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer discovery, 2019, Volume: 9, Issue:9 Topics: Age Factors; Animals; Antigen Presentation; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; CTLA-4 Antigen; Female; Humans; Interferon-gamma; Interferons; Mice; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xanthones; Xenograft Model Antitumor Assays	2019

Article

Year

Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.

Cancer discovery, 2019, Volume: 9, Issue:9

Topics: Age Factors; Animals; Antigen Presentation; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; CTLA-4 Antigen; Female; Humans; Interferon-gamma; Interferons; Mice; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xanthones; Xenograft Model Antitumor Assays

2019